Patents by Inventor Samarth Kulkarni

Samarth Kulkarni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230396704
    Abstract: Systems, devices, and methods for generating and sending messages are described. messages are autonomously generated by at least one processor by identifying environmental context of a device, system, or user, such that minimal input is required from the user. Environmental context can include at least time, date, calendar entries, user activity, location, physical environment, message history, and relationship between users. Messages can also be generated by generating a first portion of a message, and having the user select a second portion to complete the message. Recipients for a message can be autonomously determined based on environmental context and content of a message to be sent.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 7, 2023
    Inventors: Gabriel Reyes, Lee Payne, Samarth Singhal, Sushant Kulkarni, Angela Krone, Samuel Legge
  • Patent number: 11801313
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN10A gene in a cell by genome editing.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 31, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20230330270
    Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 19, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20230279439
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.
    Type: Application
    Filed: October 3, 2022
    Publication date: September 7, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20230227855
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with DMPK whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of DMPK gene in a cell by genome editing.
    Type: Application
    Filed: June 28, 2022
    Publication date: July 20, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Patent number: 11564997
    Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 31, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Patent number: 11559588
    Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN1 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA1). Also provided are materials and methods for editing a ATXN1 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN1 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN1 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN1 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN1 related condition or disorder.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 24, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20220364082
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL4 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL4 gene in a cell by genome editing.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 17, 2022
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20220340897
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with APOCIII whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of APOCIII gene in a cell by genome editing.
    Type: Application
    Filed: May 2, 2022
    Publication date: October 27, 2022
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Patent number: 11459587
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 4, 2022
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Patent number: 11427838
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with DMPK whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of DMPK gene in a cell by genome editing.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: August 30, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Patent number: 11407997
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Primary Hyperoxaluria Type 1 (PH1). The present application also provides materials and methods for editing an AGXT gene in a cell by genome editing. The present application also provides materials and methods for altering a contiguous genomic sequence of an AGXT gene in a cell. In addition, the present application provides one or more gRNAs for editing an AGXT gene. The present application also provides a therapeutic comprising at least one or more gRNAs for editing an AGXT gene. In addition, the present application provides a therapeutic for treating a patient with an AGXT related condition or disorder.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: August 9, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20220047722
    Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN1 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA1). Also provided are materials and methods for editing a ATXN1 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN1 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN1 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN1 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN1 related condition or disorder.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 17, 2022
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
  • Patent number: 11174469
    Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo. In addition, the present disclosure provides materials and methods for editing and/or modulating the expression of SOD1 gene in a cell by genome editing.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 16, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Publication number: 20210180091
    Abstract: Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and/or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.
    Type: Application
    Filed: October 26, 2018
    Publication date: June 17, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra, Chad Albert Cowan, Ante Sven Lundberg, Samarth Kulkarni, Todd Douglass Borland
  • Publication number: 20200248168
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with PCSK9 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of PCSK9 gene in a cell by genome editing.
    Type: Application
    Filed: February 15, 2018
    Publication date: August 6, 2020
    Inventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Yvonne Sarah ARATYN, Roman Lvovitch BOGORAD, Hari Kumar PADMANABHAN
  • Publication number: 20200216857
    Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN2 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA2). Also provided are materials and methods for editing a ATXN2 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN2 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN2 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN2 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN2 related condition or disorder.
    Type: Application
    Filed: February 21, 2018
    Publication date: July 9, 2020
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
  • Publication number: 20200157565
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.
    Type: Application
    Filed: February 21, 2018
    Publication date: May 21, 2020
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn
  • Publication number: 20200123570
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with APOCIII whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of APOCIII gene in a cell by genome editing.
    Type: Application
    Filed: June 29, 2017
    Publication date: April 23, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Ante Sven LUNDBERG, Lawrence KLEIN, Samarth KULKARNI, Hari Kumar PADMANABHAN
  • Publication number: 20200095579
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with LAMA2, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Merosin-deficient Cogenital Muscular Dystrophy (MDCMD). The present application also provides materials and methods for editing a LAMA2 gene in a cell by genome editing. The present application also provides materials and methods for altering a contiguous genomic sequence of a LAMA2 gene in a cell. In addition, the present application provides one or more gRNAs for editing a LAMA2 gene. The present application also provides a therapeutic comprising at least one or more gRNAs for editing a LAMA2 gene. In addition, the present application provides a therapeutic for treating a patient with a LAMA2 related condition or disorder.
    Type: Application
    Filed: February 14, 2018
    Publication date: March 26, 2020
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN